New Senate funding drafts would preserve a barrier to regulated adult-use cannabis sales in Washington, D.C., while accompanying transportation language urges continued cannabis drug testing in safety-sensitive work. The documents show how several federal cannabis policies can move on separate tracks even as medical-marijuana rescheduling changes another part of the system.
The Senate Appropriations Committee released the materials November 16. They are proposals for fiscal year 2027, not newly enacted permissions or restrictions that readers should assume already replaced current law. The committee’s publication makes its proposed approach visible; it does not establish that Congress has agreed to every provision.
Tom Angell’s November 19 report for Marijuana Moment drew attention to the cannabis language across the separate bills and explanatory statements. Reading the underlying texts matters because a bill provision, a committee instruction and a request for research serve different purposes.
The D.C. provision would retain a spending restriction
Section 809 of the proposed Financial Services and General Government bill addresses the use of funds for drug-policy changes. Its District-specific subsection would prevent spending available to the D.C. government from being used to enact laws or rules legalizing or reducing penalties for specified substances for recreational purposes.
The wording reaches both Schedule I substances and tetrahydrocannabinol derivatives. That matters when assessing claims that moving a category of marijuana to another federal schedule would, by itself, remove every obstacle to adult-use sales in the capital. The proposed spending language is not written solely around a single schedule reference.
This is also different from announcing the closure of the District’s medical program or creating a federal retail license. The question here is whether local government can use its funds to build a recreational regulatory framework. A person’s ability to participate in an existing medical system and the government’s ability to establish an adult-use market are separate issues.
Transportation language focuses on safety-sensitive work
The Transportation and Housing explanatory statement directs the Department of Transportation to maintain current cannabis testing requirements. It identifies aviation, trucking, rail, transit and pipelines, alongside relevant federal and DOT positions, as settings where potential impairment is a public-safety concern.
The statement says the absence of a scientifically validated relationship between cannabis-metabolite levels and impairment is a reason to avoid relaxing the requirements. It also urges coordination with Health and Human Services and the National Highway Traffic Safety Administration on improved detection methods and alternative testing matrices.
That is a committee position about workforce safeguards and research needs. It is not a finding that every positive test establishes present impairment, or a newly validated impairment threshold. Those distinctions are particularly important when discussing cannabis, because detecting prior exposure and establishing someone’s condition at a particular moment are different questions.
Nor does this paragraph announce that every worker in the country is covered by DOT testing. Its scope concerns transportation and the federal positions described in the statement. Readers should avoid turning a targeted proposal into a claim about all employment or treating rescheduling news as a personal exemption from an applicable workplace rule.
Research concerns appear in another statement
The separate Labor and Health explanatory statement expresses concern that Schedule I restrictions limit research involving several drugs, including marijuana and its component chemicals. It notes difficulties researchers face obtaining sources, including dispensary products, and acknowledges work by the National Institute on Drug Abuse on those barriers.
Elsewhere, that statement calls for expanded work on the potential therapeutic effects of psychedelics and encourages attention to the workforce needed for emerging treatments. Such language supports investigation; it does not demonstrate that a particular substance is safe or effective for a particular patient, or authorize general clinical access to an unapproved treatment.
Taken together, these provisions show that support for additional research does not necessarily mean support for every retail-policy change. A committee can seek better evidence while retaining restrictions in another area. That combination is more precise than describing the entire funding package as either full cannabis reform or a single blanket prohibition.
What changes next depends on legislation
The committee’s release covers several agencies and policy areas, so an item appearing in one statement should not be assumed to govern all the others. The final legislative text, its enactment and the agencies’ implementation will matter more than a headline summarizing the package.
For D.C. readers, the immediate takeaway is that this Senate proposal retains the adult-use spending obstacle. For transportation workers, the statement signals continuity in the committee’s testing position. For researchers, it recognizes access barriers without declaring them solved. None of those points amounts to a new, universal rule for cannabis consumers.
Illustrative meeting-room stock photograph; not the U.S. Senate, a committee hearing or a D.C. government chamber. Photo: Werner Pfennig / Pexels.